Indapta Therapeutics Inc.
Using targeted NK Cells, a new class of Immuno-Oncology products, to drive the next major revolution in safe, allogeneic cancer therapies.
Full Description
First-in-class, off-the-shelf, allogeneic, Natural Killer cell immuno-oncology (IO) product. Stanford University and UC Davis Scientific Founders. Indapta has partnered with UH. Indapta is set to rapidly commercialize the field's most potent cancer-killing NK cell product. It expects that its allogeneic, First In Class Immuno Oncology NK cell product platform will cure multiple forms of cancer - on par with CAR-T yet extremely safely, with no GVHD, and with efficientlarge scale GMP manufacturing with with low COGS. Indapta believes its product platform will drive the next critical phase of cancer therapy evolution post CAR-T.
Preferential subset of natural killer (NK) cells kills cancer in combination with monoclonal antibodies, (mAbs) far betterthan mAbs alone or conventional NK cells and mAbs.

Super G-NK cells from population of super donors safely and dramatically enhance cancer killing of existing cancermAbs

FceRIy-deficient NK cells (G-NK cells) cells augment efficacy of mAb therapy to kill cancer by causing far stronger Antibody Dependent Cell Mediated Cytotoxicity (ADCC) than mAb alone.

Relative simplicity of combining FDA approved antibodies with G-NK cells that are naturally pre-configured with powerful cytotoxic potency (no need to engineer cells) results in far faster time to market with less capital required.